Gastrointestinal Cancer – Page 3 – Medical News Asia

Trifluridine/tipiracil combination FDA approved for metastatic gastric or GEJ adenocarcinoma

23 February 2019/0 Comments/in Gastrointestinal Cancer, US FDA Onc\Haem Approvals, Oncology, Chemotherapy/by scienterrific

On 22 February 2019, the FDA approved the fixed combination tablets of the nucleoside metabolic inhibitor trifluridine plus the thymidine phosphorylase inhibitor tipiracil (Lonsurf®, Taiho Pharmaceutical) for the treatment of adult metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma patients pretreated with two or more prior lines of chemotherapy including a fluoropyrimidine, a platinum, and either a taxane or irinotecan plus (when appropriate) HER2/neu-targeted therapy.

Trastuzumab-biosimilar Ontruzant® FDA approved in several indications

21 January 2019/0 Comments/in Breast Cancer, Gastrointestinal Cancer, US FDA Onc\Haem Approvals, Oncology, Targeted Therapies/by scienterrific

On 18 January 2019, the FDA approved the Herceptin®-biosimilar Ontruzant® (trastuzumab-dttb, Samsung BioEpsis), a HER2/neu receptor antagonist, for patients with HER2-overexpressing (HER2+) breast cancer in the adjuvant and metastatic setting, and in metastatic HER2+ gastric cancer patients. Ontruzant® was approved as biosimilar, not as an interchangeable product.

Cabozantinib FDA approved in HCC patients failing sorafenib

17 January 2019/0 Comments/in Gastrointestinal Cancer, US FDA Onc\Haem Approvals, Oncology, Targeted Therapies/by scienterrific

On 14 January 2019, the FDA approved cabozantinib (Cabometyx®, Exelixis) for hepatocellular carcinoma (HCC) patients previously treated with sorafenib.

The Emerging Role of Yttrium-90 in Primary and Metastatic Liver Cancer

22 November 2018/Enter your password to view comments./in Gastrointestinal Cancer, Oncology, Radioactive Drugs, Radiology/by Adrian YIP

There is no excerpt because this is a protected post.

Pembrolizumab FDA approved in hepatocellular carcinoma patients pretreated with sorafenib

19 November 2018/1 Comment/in Gastrointestinal Cancer, US FDA Onc\Haem Approvals, Immunotherapy/by scienterrific

On 9 November 2018, the FDA granted accelerated approval to pembrolizumab (Keytruda®, Merck) for the treatment of patients with hepatocellular carcinoma (HCC) previously treated with sorafenib.

I-O in Special Populations: Chronic Viral Hepatitis Carriers

18 November 2018/Enter your password to view comments./in Gastrointestinal Cancer, Oncology, Immunotherapy, irAE Management/by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

ESMO 2018 HCC: The ESMO18 hepatobiliary cancer track summarised

3 November 2018/1 Comment/in Conferences, Gastrointestinal Cancer, ESMO 2018 Annual Meeting, Oncology, Immunotherapy, Targeted Therapies, Translational Research/by Stijn van den Borne, MSc

Whereas this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2018) boasted two Phase III studies and four Phase II studies with notable results in hepatocellular carcinoma (HCC), the trend did not continue to the European Society for Medical Oncology Conference (ESMO 2018), held in Münich, Germany between October 19-23, 2018. The focus for this years ESMO was mostly on biliary-tract cancers (BTC). Welcome to the hepatobiliary track of ESMO 2018.

Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA

15 October 2018/0 Comments/in Medical News Asia, Gastrointestinal Cancer, Lung Cancer, Oncology, Immunotherapy, Targeted Therapies/by scienterrific

SUZHOU, China, Oct. 14, 2018 /PRNewswire/ — The combination therapy of novel programmed death 1 (PD-1) antibody IBI308 (sintilimab, Innovent Biologics) with biosimilar bevacizumab antibody IBI305 (Innovent Biologics) has received the investigational new drug (IND) application for clinical development approval by the National Medical Products Administration (NMPA, formerly known as CFDA) in China.

CheckMate 032: Nivolumab +/- ipilimumab for metastatic esophagogastric cancer

18 August 2018/0 Comments/in Gastrointestinal Cancer, Oncology, Immunotherapy, Translational Research/by scienterrific

Immunotherapy with either nivolumab (Opdivo®, Bristol-Myers Squibb) alone or the combination nivolumab plus ipilimumab (Yervoy®, Bristol-Myers Squibb) in patients with chemotherapy-refractory esophagogastric cancer leads to durable responses and encouraging long-term overall survival with a manageable safety profile, concluded the investigators of the CheckMate 032 study.

Lenvatinib FDA approved for 1st-line treatment of HCC

18 August 2018/1 Comment/in Gastrointestinal Cancer, US FDA Onc\Haem Approvals, Oncology, Targeted Therapies/by scienterrific

On August 16, 2018 the FDA approved lenvatinib (Lenvima®, Eisai) for the first-line treatment of hepatocellular carcinoma (HCC) patients not amenable for curative surgery.